Regenicin 

$0
5
+$0+0% Wednesday 20:00

統計

當日最高
0
當日最低
0
52週最高
0.01
52週最低
0
成交量
25,000
平均成交量
8,203
市值
15,348
市盈率
-
股息收益率
-
股息
-

收益

12Aug預期
Q2 2020
Q4 2020
Q1 2021
Q2 2021
Q4 2021
Q1 2022
Q2 2022
-0
-0
-0
0
預期每股收益
N/A
實際每股收益
-0.0012

人們還關注

此列表基於在 Stock Events 上關注 RGIN 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Miscellaneous Commercial Services
Manufacturing
Commercial Services
Industrial and Commercial Fan and Blower and Air Purification Equipment Manufacturing
Biotechnology
Health Technology
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. The company's product portfolio includes NovaDerm, a multi-layered tissue-engineered living skin and cultured skin substitute product for the treatment of burns; and TempaDerm to treat smaller wound areas on patients, such as ulcers. Its products are used to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds, and various plastic surgery procedures. The company was formerly known as Windstar, Inc. and changed its name to Regenicin, Inc. in July 2010. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey.
Show more...
首席執行官
員工
3
國家
US
ISIN
US75887Q1022

上市公司